DE69725897D1 - Behandlung von störungen mittels interleukin-9 - Google Patents

Behandlung von störungen mittels interleukin-9

Info

Publication number
DE69725897D1
DE69725897D1 DE69725897T DE69725897T DE69725897D1 DE 69725897 D1 DE69725897 D1 DE 69725897D1 DE 69725897 T DE69725897 T DE 69725897T DE 69725897 T DE69725897 T DE 69725897T DE 69725897 D1 DE69725897 D1 DE 69725897D1
Authority
DE
Germany
Prior art keywords
treatment
interleukin
interference
thyroiditis
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725897T
Other languages
English (en)
Other versions
DE69725897T2 (de
Inventor
Jean-Christophe Renauld
Mary-Christine Many
Francois Huaux
Dominique Lison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Application granted granted Critical
Publication of DE69725897D1 publication Critical patent/DE69725897D1/de
Publication of DE69725897T2 publication Critical patent/DE69725897T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/206—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69725897T 1996-08-30 1997-08-29 Behandlung von störungen mittels interleukin-9 Expired - Lifetime DE69725897T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/706,302 US5830454A (en) 1996-08-30 1996-08-30 Method for treating cell mediated autoimmune disorders using interleukin-9
US706302 1996-08-30
PCT/US1997/015264 WO1998008545A1 (en) 1996-08-30 1997-08-29 Methods for treating disorders by using interleukin-9 and its antagonists

Publications (2)

Publication Number Publication Date
DE69725897D1 true DE69725897D1 (de) 2003-12-04
DE69725897T2 DE69725897T2 (de) 2004-08-26

Family

ID=24837006

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725897T Expired - Lifetime DE69725897T2 (de) 1996-08-30 1997-08-29 Behandlung von störungen mittels interleukin-9

Country Status (11)

Country Link
US (2) US5830454A (de)
EP (1) EP1007093B1 (de)
JP (1) JP2000517322A (de)
AT (1) ATE252911T1 (de)
AU (1) AU721908B2 (de)
CA (1) CA2263935A1 (de)
DE (1) DE69725897T2 (de)
DK (1) DK1007093T3 (de)
ES (1) ES2210569T3 (de)
PT (1) PT1007093E (de)
WO (1) WO1998008545A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
US6328955B1 (en) * 2000-01-25 2001-12-11 Ludwig Institute For Cancer Research Method for regulating IL-10 with IL-9, and applications thereof
US6586336B2 (en) 2001-08-31 2003-07-01 Oriol, Inc. Chemical-mechanical-polishing station
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0526000D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Cytokine receptor
EP3184117B1 (de) 2011-03-22 2020-01-08 The Brigham And Women's Hospital, Inc. Zusammensetzungen und deren verwendung zur krebsbehandlung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5414071A (en) * 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
WO1991014767A1 (en) * 1990-03-23 1991-10-03 Ludwig Institute For Cancer Research Method for enhanced growth and proliferation of mast cells
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
CA2230240C (en) * 1995-08-24 2009-08-18 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9

Also Published As

Publication number Publication date
WO1998008545A1 (en) 1998-03-05
PT1007093E (pt) 2004-03-31
EP1007093A1 (de) 2000-06-14
DE69725897T2 (de) 2004-08-26
AU4171297A (en) 1998-03-19
CA2263935A1 (en) 1998-03-05
EP1007093A4 (de) 2000-11-08
JP2000517322A (ja) 2000-12-26
ATE252911T1 (de) 2003-11-15
DK1007093T3 (da) 2004-01-26
US5830454A (en) 1998-11-03
EP1007093B1 (de) 2003-10-29
AU721908B2 (en) 2000-07-20
US5935929A (en) 1999-08-10
ES2210569T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
DE69617469D1 (de) Behandlung von multipler sklerose
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
ATE250412T1 (de) Muskarinische antagonisten zur behandlung von presbyopie
ATE232082T1 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
BR9709068A (pt) Processo de tratamento.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69725897D1 (de) Behandlung von störungen mittels interleukin-9
DE69617729T2 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
DE69518438T2 (de) Behandlung von übereregten nervenzellenfunktionen
ATE211920T1 (de) Verwendung von relaxin als schmerzstiller und - dämpfer für starken schmerz
EP0255224A3 (de) Cyclische und verbrückt cyclische Analoge von Somatostatin, verwendbar als analgetische Arzneimittel
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
RU93057223A (ru) Способ лечения параличей и парезов
RU96115416A (ru) Способ лечения больных с частичной атрофией зрительных нервов
RU95116393A (ru) Способ лечения заболеваний спинного мозга
UA15554A (uk) Спосіб прогhозуваhhя ефективhості рефлексотерапії за лазориком
GR950100293A (el) Γλουτο- ανορθωτικο βιομαγνητικο μασσαζοκαλσον αδυνατισματος.
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
RU92005796A (ru) Способ лечебного информационно-энергетического воздействия при псориазе
RU96101676A (ru) Способ лечения алкогольной зависимости
UA27049C2 (uk) Спосіб профілактики больового сиhдрому при хворобах периферичhої hервової системи

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition